Production and Characterization of a Recombinant Antibody Fragment for Cancer Diagnosis
Author Information
Author(s): G Denton, M Sekowski, DIR Spencer, ODM Hughes, A Murray, H Denley, SJB Tendler, MR Price
Primary Institution: University of Nottingham
Hypothesis
Can a recombinant single-chain fragment of the anti-MUC1 monoclonal antibody C595 be produced that retains its binding activity to human carcinomas?
Conclusion
The recombinant C595 scFv retains the ability to bind to tumor cells and MUC1 antigen, indicating its potential for diagnostic and therapeutic applications.
Supporting Evidence
- The recombinant scFv showed similar activity to the parent antibody in various assays.
- Immunohistochemistry confirmed the binding of the scFv to MUC1 antigen on tumor tissues.
- Fluorescence quenching experiments demonstrated the binding capacity of the scFv to MUC1-related peptides.
Takeaway
Scientists made a special protein that can stick to cancer cells, which might help doctors find and treat cancer better.
Methodology
The study involved producing a recombinant antibody fragment using hybridoma cells, PCR, and phage display technology, followed by purification and various analyses to confirm its activity.
Limitations
The study does not specify the limitations of the recombinant scFv in clinical settings.
Want to read the original?
Access the complete publication on the publisher's website